{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:15:19Z","timestamp":1778919319756,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":20,"publisher":"Springer US","isbn-type":[{"value":"9781071647370","type":"print"},{"value":"9781071647387","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-4738-7_1","type":"book-chapter","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:20:31Z","timestamp":1759281631000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DG9-Conjugated Morpholino-Based Exon 51-Skipping Therapy for Duchenne Muscular Dystrophy"],"prefix":"10.1007","author":[{"given":"Md Nur Ahad","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Edellein","family":"Sutanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A (2021) Duchenne muscular dystrophy. Nat Rev Dis Primers 7:1\u201319","journal-title":"Nat Rev Dis Primers"},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/jhg.2017.57","volume":"62","author":"A Nakamura","year":"2017","unstructured":"Nakamura A (2017) Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy. J Hum Genet 62:871\u2013876","journal-title":"J Hum Genet"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/jcm9062004","volume":"9","author":"K Dhuri","year":"2020","unstructured":"Dhuri K et al (2020) Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med 9:2004","journal-title":"J Clin Med"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1756285612472386","volume":"6","author":"WKM Liew","year":"2013","unstructured":"Liew WKM, Kang PB (2013) Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. Ther Adv Neurol Disord 6:147\u2013160","journal-title":"Ther Adv Neurol Disord"},{"key":"1_CR5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112546119","volume":"119","author":"KRQ Lim","year":"2022","unstructured":"Lim KRQ et al (2022) Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. Proc Natl Acad Sci 119:e2112546119","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR6","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig M et al (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45:498\u2013506","journal-title":"Am J Hum Genet"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M (2021) Casimersen: first approval. Drugs 81:875\u2013879","journal-title":"Drugs"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545","journal-title":"Drug Des Devel Ther"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","volume":"56","author":"S Anwar","year":"2020","unstructured":"Anwar S, Yokota T (2020) Golodirsen for Duchenne muscular dystrophy. Drugs Today (Barc) 56:491\u2013504","journal-title":"Drugs Today (Barc)"},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","volume":"55","author":"R Roshmi","year":"2019","unstructured":"Roshmi R, R, & Yokota, T. (2019) Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today 55:627","journal-title":"Drugs Today"},{"key":"1_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","volume":"45","author":"MK Tsoumpra","year":"2019","unstructured":"Tsoumpra MK et al (2019) Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine 45:630\u2013645","journal-title":"EBioMedicine"},{"key":"1_CR12","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","volume":"1798","author":"HM Moulton","year":"2010","unstructured":"Moulton HM, Moulton JD (2010) Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochimica et Biophysica Acta (BBA) \u2013 Biomembranes 1798:2296\u20132303","journal-title":"Biochimica et Biophysica Acta (BBA) \u2013 Biomembranes"},{"key":"1_CR13","first-page":"24","volume":"31","author":"L Politano","year":"2012","unstructured":"Politano L, Nigro G (2012) Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. Acta Myol 31:24\u201330","journal-title":"Acta Myol"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ymthe.2018.10.011","volume":"27","author":"KRQ Lim","year":"2019","unstructured":"Lim KRQ et al (2019) Efficacy of multi-exon skipping treatment in Duchenne muscular dystrophy dog model neonates. Mol Ther 27:76\u201386","journal-title":"Mol Ther"},{"key":"1_CR15","first-page":"1202","volume":"11","author":"Q Nguyen","year":"2019","unstructured":"Nguyen Q, Yokota T (2019) Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy. Am J Transl Res 11:1202\u20131218","journal-title":"Am J Transl Res"},{"key":"1_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244215","volume":"15","author":"A Yavas","year":"2020","unstructured":"Yavas A et al (2020) Detailed genetic and functional analysis of the hDMDdel52\/mdx mouse model. PLoS One 15:e0244215","journal-title":"PLoS One"},{"key":"1_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193289","volume":"13","author":"M Veltrop","year":"2018","unstructured":"Veltrop M et al (2018) A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. PLoS One 13:e0193289","journal-title":"PLoS One"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0022-510X(94)00276-T","volume":"129","author":"C Pastoret","year":"1995","unstructured":"Pastoret C, Sebille A (1995) mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 129:97\u2013105","journal-title":"J Neurol Sci"},{"key":"1_CR19","doi-asserted-by":"publisher","unstructured":"Aslesh T, Erkut E, Ren J, Lim KRQ, Woo S, Hatlevig S, Moulton HM, Gosgnach S, Greer J, Maruyama R, Yokota T (2023) DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration. JCI Insight 8(5). https:\/\/doi.org\/10.1172\/jci.insight.160516","DOI":"10.1172\/jci.insight.160516"},{"key":"1_CR20","doi-asserted-by":"publisher","unstructured":"Shah MNA, Wilton-Clark H, Haque F, Powell B, Sutanto LE, Maradiya R, Zhabyeyev P, Roshmi RR, Anwar S, Aslesh T, Lim KRQ, Maruyama R, Bigot A, Young CS, Bittner S, Spencer MJ, Moulton HM, Oudit GY, Yokota T (2025) DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function. Nat Commun 16(1). https:\/\/doi.org\/10.1038\/s41467-025-59494-8","DOI":"10.1038\/s41467-025-59494-8"}],"container-title":["Methods in Molecular Biology","Splice Switching"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4738-7_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:58:22Z","timestamp":1778918302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4738-7_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"ISBN":["9781071647370","9781071647387"],"references-count":20,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4738-7_1","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"1 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}